Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 5Lung Neoplasms 3Adenocarcinoma 3Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Sarcoma, Alveolar Soft Part 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Metastatic Small Intestinal Adenocarcinoma 1Metastatic Gastric Adenocarcinoma 1Head and Neck Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Colorectal Neoplasms 1Clinical Stage IVB Gastric Cancer AJCC v8 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Gastric Adenocarcinoma × Ramucirumab × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡